MedTrace Logo

Intelligent Screening and Precision Diagnosis of Prostate Cancer Based on Multimodal Data

NCT07631806 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-06-17

No results posted yet for this study

Summary

This project aims to develop a precision screening and diagnostic solution for prostate cancer based on multimodal artificial intelligence, focusing on addressing the diagnostic challenge in patients within the PSA "gray zone" of 4-10 ng/mL. The project will integrate multidimensional information including ctDNA liquid biopsy, routine laboratory data, and prostate ultrasound images to develop three models: a ctDNA-based multimodal AI prediction model, a routine laboratory data-assisted decision model, and an ultrasound image AI-assisted diagnostic model. On this basis, a multimodal AI fusion decision system will be established to automatically generate individualized risk assessment reports and diagnostic recommendations. Additionally, a closed-loop mechanism of "clinical use - data feedback - model optimization" will be constructed to continuously iterate model parameters using pathological gold standards, thereby improving predictive accuracy in our hospital population. The project will form a generalizable precision diagnostic workflow, reduce unnecessary biopsies in "gray zone" patients, and provide an implementable in-hospital solution for precision medicine in prostate cancer.

Conditions

  • Prostate Cancer With PSA Gray Zone

Sponsors & Collaborators

  • Guangxi Medical University

    lead OTHER

Eligibility

Min Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2028-05-01
Completion
2028-05-01

Countries

  • China

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07631806 on ClinicalTrials.gov